Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
138
mi
from 43215
Cleveland, OH
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Foundation
138
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
841
mi
from 43215
Oklahoma City, OK
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
University of Oklahoma Health Sciences Center
841
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
2020
mi
from 43215
Clackamas, OR
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Clackamas Radiation Oncology Center
2020
mi
from 43215
Clackamas, OR
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
2022
mi
from 43215
Clackamas, OR
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Providence Oncology and Hematology Care Southeast
2022
mi
from 43215
Clackamas, OR
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
2117
mi
from 43215
Coos Bay, OR
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Bay Area Hospital
2117
mi
from 43215
Coos Bay, OR
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
2042
mi
from 43215
Newberg, OR
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Providence Newberg Medical Center
2042
mi
from 43215
Newberg, OR
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
mi
from 43215
Oregon City, OR
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Providence Willamette Falls Medical Center
mi
from 43215
Oregon City, OR
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
2026
mi
from 43215
Portland, OR
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Providence Portland Medical Center
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
417
mi
from 43215
Abington, PA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Abington Memorial Hospital
417
mi
from 43215
Abington, PA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
397
mi
from 43215
Allentown, PA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Lehigh Valley Hospital-Cedar Crest
397
mi
from 43215
Allentown, PA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
405
mi
from 43215
Bethlehem, PA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Lehigh Valley Hospital - Muhlenberg
405
mi
from 43215
Bethlehem, PA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
391
mi
from 43215
Chadds Ford, PA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Christiana Care Health System-Concord Health Center
391
mi
from 43215
Chadds Ford, PA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
362
mi
from 43215
Ephrata, PA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Ephrata Cancer Center
362
mi
from 43215
Ephrata, PA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
307
mi
from 43215
Gettysburg, PA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Adams Cancer Center
307
mi
from 43215
Gettysburg, PA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
320
mi
from 43215
Hanover, PA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Cherry Tree Cancer Center
320
mi
from 43215
Hanover, PA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
414
mi
from 43215
Philadelphia, PA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
University of Pennsylvania:Abramson Cancer Center
414
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
355
mi
from 43215
Easley, SC
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Greenville Health System Cancer Institute-Easley
355
mi
from 43215
Easley, SC
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
355
mi
from 43215
Greenville, SC
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Greenville Health System Cancer Institute-Andrews
355
mi
from 43215
Greenville, SC
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
360
mi
from 43215
Greenville, SC
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Greenville Health System Cancer Institute-Butternut
360
mi
from 43215
Greenville, SC
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
353
mi
from 43215
Greenville, SC
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Greenville Health System Cancer Institute/Eastside
353
mi
from 43215
Greenville, SC
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
360
mi
from 43215
Greenville, SC
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Greenville Health System Cancer Institute-Faris
360
mi
from 43215
Greenville, SC
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
358
mi
from 43215
Greenville, SC
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Greenville Memorial Hospital
358
mi
from 43215
Greenville, SC
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
358
mi
from 43215
Greenville, SC
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Saint Francis Cancer Center
358
mi
from 43215
Greenville, SC
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
355
mi
from 43215
Greenville, SC
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Saint Francis Hospital
355
mi
from 43215
Greenville, SC
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
352
mi
from 43215
Greer, SC
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Greenville Health System Cancer Institute-Greer
352
mi
from 43215
Greer, SC
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
364
mi
from 43215
Seneca, SC
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Greenville Health System Cancer Institute-Seneca
364
mi
from 43215
Seneca, SC
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
351
mi
from 43215
Spartanburg, SC
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Greenville Health System Cancer Institute-Spartanburg
351
mi
from 43215
Spartanburg, SC
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
362
mi
from 43215
Chattanooga, TN
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Hospital
362
mi
from 43215
Chattanooga, TN
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
354
mi
from 43215
Hixson, TN
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Pulmonary Medicine Center of Chattanooga-Hixson
354
mi
from 43215
Hixson, TN
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
356
mi
from 43215
Ooltewah, TN
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial GYN Plus
356
mi
from 43215
Ooltewah, TN
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
1511
mi
from 43215
Salt Lake City, UT
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Huntsman Cancer Institute at University of Utah
1511
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
2076
mi
from 43215
Aberdeen, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Providence Regional Cancer System-Aberdeen
2076
mi
from 43215
Aberdeen, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
2021
mi
from 43215
Anacortes, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Care Center at Island Hospital
2021
mi
from 43215
Anacortes, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
1999
mi
from 43215
Bellevue, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Swedish Cancer Institute-Eastside Oncology Hematology
1999
mi
from 43215
Bellevue, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
2015
mi
from 43215
Bellingham, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
PeaceHealth Saint Joseph Medical Center
2015
mi
from 43215
Bellingham, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
2020
mi
from 43215
Bremerton, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Harrison HealthPartners Hematology and Oncology-Bremerton
2020
mi
from 43215
Bremerton, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
2020
mi
from 43215
Bremerton, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Harrison Medical Center
2020
mi
from 43215
Bremerton, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
2007
mi
from 43215
Burien, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Highline Medical Center-Main Campus
2007
mi
from 43215
Burien, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
2036
mi
from 43215
Centralia, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Providence Regional Cancer System-Centralia
2036
mi
from 43215
Centralia, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
2007
mi
from 43215
Edmonds, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Swedish Medical Center-Edmonds
2007
mi
from 43215
Edmonds, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
1990
mi
from 43215
Enumclaw, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Saint Elizabeth Hospital
1990
mi
from 43215
Enumclaw, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
2001
mi
from 43215
Everett, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Providence Regional Cancer Partnership
2001
mi
from 43215
Everett, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
2006
mi
from 43215
Federal Way, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Saint Francis Hospital
2006
mi
from 43215
Federal Way, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
1993
mi
from 43215
Issaquah, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Swedish Cancer Institute-Issaquah
1993
mi
from 43215
Issaquah, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
2028
mi
from 43215
Lacey, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Providence Regional Cancer System-Lacey
2028
mi
from 43215
Lacey, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
2014
mi
from 43215
Lakewood, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Saint Clare Hospital
2014
mi
from 43215
Lakewood, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
2021
mi
from 43215
Poulsbo, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Harrison HealthPartners Hematology and Oncology-Poulsbo
2021
mi
from 43215
Poulsbo, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
2006
mi
from 43215
Seattle, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Minor and James Medical, PLLC
2006
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
2006
mi
from 43215
Seattle, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Northwest Hospital
2006
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
2006
mi
from 43215
Seattle, WA
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Pacific Gynecology Specialists
2006
mi
from 43215
Seattle, WA
Click here to add this to my saved trials